CN102600255A - Coronary disease treatment capsule - Google Patents
Coronary disease treatment capsule Download PDFInfo
- Publication number
- CN102600255A CN102600255A CN2012100878746A CN201210087874A CN102600255A CN 102600255 A CN102600255 A CN 102600255A CN 2012100878746 A CN2012100878746 A CN 2012100878746A CN 201210087874 A CN201210087874 A CN 201210087874A CN 102600255 A CN102600255 A CN 102600255A
- Authority
- CN
- China
- Prior art keywords
- radix
- rhizoma chuanxiong
- salviae miltiorrhizae
- flos carthami
- panacis quinquefolii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a traditional Chinese medical capsule for treatment of coronary diseases and a preparation method thereof. The capsule is prepared with red-rooted salvia, American ginseng, safflower, ligusticum wallichii, pseudo-ginseng, leech, ground beeltle, prepared radix aconiti carmichaeli and other raw materials. The capsule has a reasonable structure, a delicate formula and no obvious toxic and side effects, and has the advantages of promoting blood circulation to remove blood stasis, relaxing blood vessels, increasing myocardial blood supply and oxygen supply, reducing platelet aggregation, providing calcium antagonists, eliminating free radicals and treating coronary atherosclerosis. The total efficiency of treatment of the coronary diseases is 100 percent.
Description
Technical field
The present invention relates to a kind of Chinese medicine, relate in particular to a kind of Chinese medicinal capsule of treating coronary heart disease and preparation method thereof.
Background technology
Coronary heart disease is the healthy cardiovascular disease of a kind of serious harm human body, is commonly encountered diseases, frequently-occurring disease clinically.According to incompletely statistics, China's coronary heart disease death rate is growth trend year by year, an important problem that therefore with Chinese medicine the treatment research and the Prevention Research of coronary heart disease is medical domain.In recent years, Chinese medicine is being obtained considerable progress in treatment aspect the primary disease, becomes one of the means of the Comprehensive Treatment of coronary heart disease.In view of coronary heart disease is common clinical, frequently-occurring disease, strengthen top priority to its treatment research person that become the clinical position.
Chinese medicine medicine treatment coronary heart disease angina cordis has quiet long history and rich experience.The organic conception of the traditional Chinese medical science, distinguish that disease executing controlled, treatment that advantages such as the effectiveness of dynamic equilibrium and Chinese medicine treatment primary disease, innocuousness, persistence, multiformity are suitable for complicated and diversified coronary heart disease.Multidirectional research is observed and was confirmed already, sending symptom, reduces recurrence, and Chinese medicine medical treatment in the aspect of improving the quality of living is imitated obviously definite.Taking Chinese medicine for a long time and can reside and prevent integrating prevention, treatment, rehabilitation in controlling, is that current treatment coronary heart disease obtains some and breaks through one of method the most likely.Therefore, give full play to the advantage of motherland's medical science,, seek and develop effective prescription of treatment coronary heart disease, have important theoretical meaning and use value in conjunction with the modern study achievement.
Summary of the invention
The object of the invention just provides a kind of Chinese medicine preparation that coronary heart disease has obvious curative effects of treating.The object of the invention can be realized through following scheme: arklemin open capsule according to the invention is to be that the preparation of raw material of weight portion forms: Radix Salviae Miltiorrhizae 15-35, Radix Panacis Quinquefolii 10-30 by following dosage; Flos Carthami 10-30, Rhizoma Chuanxiong 8-21, Radix Notoginseng 3-9; Hirudo 2-8, Eupolyphaga Seu Steleophaga 2-8, Radix Aconiti Lateralis Preparata 1-3.
The preferential proportioning of above-mentioned said raw material consumption is following: Radix Salviae Miltiorrhizae 20-30, Radix Panacis Quinquefolii 15-25, Flos Carthami 15-25, Rhizoma Chuanxiong 11-18, Radix Notoginseng 4-8, Hirudo 3-7, Eupolyphaga Seu Steleophaga 3-7, Radix Aconiti Lateralis Preparata 1.5-2.5.
Above-mentioned said raw material consumption optimal proportion is following: Radix Salviae Miltiorrhizae 25, Radix Panacis Quinquefolii 21, Flos Carthami 21, Rhizoma Chuanxiong 15, Radix Notoginseng 6, Hirudo 5, Eupolyphaga Seu Steleophaga 5, Radix Aconiti Lateralis Preparata 2.
Arklemin open capsule method for preparing of the present invention is following: it is subsequent use at first the Radix Notoginseng for preparing, Hirudo, Eupolyphaga Seu Steleophaga, Radix Aconiti Lateralis Preparata to be ground into fine powder (120 order); Again with the Radix Salviae Miltiorrhizae for preparing, Rhizoma Chuanxiong, Radix Panacis Quinquefolii, Flos Carthami decocte with water twice, decocting water consumption for the first time is Radix Salviae Miltiorrhizae; Rhizoma Chuanxiong, Radix Panacis Quinquefolii, Flos Carthami gross weight 3-5 times, decocting time is 40 minutes, decocting water consumption for the second time is Radix Salviae Miltiorrhizae; Rhizoma Chuanxiong, Radix Panacis Quinquefolii, Flos Carthami gross weight 3-4 times; Decocting time 30 minutes decocts extracting solution with twice and merges filtration, filtrate for later use; Filtrating is put into concentration tank concentrate, be condensed into the fine powder that again Radix Notoginseng, Hirudo, Eupolyphaga Seu Steleophaga, Radix Aconiti Lateralis Preparata is ground behind the paste and add, carry out 100 degree oven drying at low temperatures then, pulverized 100 order fill capsules at last, the medicated powder weight of each capsule the inside is 0.5 gram.
The Radix Salviae Miltiorrhizae that the present invention is used, Rhizoma Chuanxiong, Radix Notoginseng etc. has stronger calcium channel blocking action, can alleviate coronary spasm, increases side Zhi Xunhuan, improves the ischemic region blood supply, and anticoagulant suppresses TXA
2Generation, promote blood vessel wall PGI
2Generation, vasodilator reduces viscosity of blood and packed cell volume; Reduce plasma fibrinogen content, thereby improve " Gao Ning " state of patient blood, reduce plain (ET) content of blood vessel endothelium; Play blood vessel dilating, reduce vascular resistance, coronary blood flow increasing; The used Hirudo of the present invention, Rhizoma Chuanxiong etc. impel regression of atherosclerotic plaques, and blood vessel wall inflammatory cell apoptosis improves, alleviates, the counterseal tremulous pulse continues sclerosis, recovers blood vessel elasticity.
The present invention is complete, and square structure is reasonable, and compatibility is precise and appropriate, and no obvious toxic-side effects has blood circulation promoting and blood stasis dispelling, and vasodilator increases blood supply of cardiac muscle, oxygen-supplying amount, reduction platelet aggregation, also has calcium ion antagonist and eliminates free radical, anti-coronary atherosclerosis effect.
The present invention treats the clinical report of coronary heart disease:
1, clinical data:
50 examples are organized in treatment, wherein male 32 examples, women 18 examples, age 42-76 year, 59 years old mean age, EA 31 examples, non-EA 19 examples, complicated hypertension 10 examples, diabetes 4 examples, arrhythmia 3 examples, slight 10 examples, moderate 35 examples, severe 5 examples.
Matched group 30 examples, wherein male 20 examples, women 10 examples, age 40-70 year, 55 years old mean age, EA 19 examples, non-EA 11 examples, complicated hypertension 6 examples, diabetes 3 examples, arrhythmia 4 examples, slight 6 examples, moderate 22 examples, severe 2 examples.
Two groups of age of onset, types of pain and degree all have comparability (P>0.05).
Diagnosis was with reference to national internal medicine academic conference in 1980; " suggestion of coronary heart disease name and diagnostic criteria " diagnosis and typing [CHINESE JOURNAL OF INTERNAL MEDICINE 1981,20 (4): 253], selecting has angina cordis to show effect repeatedly; Routine electrocardiogram has the ischemic ST-T changer; All cases all have the cardiopalmus of varying degree, breathe hard, and are uncomfortable in chest with chest pain and the person of making a definite diagnosis.
2, Therapeutic Method:
The treatment group adopts " arklemin open capsule " of the present invention, and each 5, every day 3 times, 30 days is a course of treatment.
The each oral sorbitrate 10mg of matched group, persantin 50mg, every day 3 times, 30 days is a course of treatment.
Two groups of period in a medicine are all stopped using, and other treats angina pectoris medicine, evaluates curative effect after the course of treatment.
3, therapeutic outcome:
3.1 criterion of therapeutical effect:
Produce effects: after 1 course of treatment, each symptom, sign disappear and ECG ST-T recovers normal.
Take a turn for the better: after 1 course of treatment, clinical symptoms, sign obviously alleviate or disappear, and being reduced in of ECG ST-T section treated more than the back rise 0.05mv, but do not reach normal level.
Invalid: after 1 course of treatment, clinical symptoms and electrocardiogram do not have any change.
3.2 result:
Treatment is organized in 50 examples, produce effects 40 examples, 10 examples that take a turn for the better, total effective rate 100%.
In matched group 30 examples, produce effects 8 examples, 18 examples that take a turn for the better, invalid 4 examples, total effective rate 86.6%.
Two groups of relatively treatment group total effective rates obviously are superior to matched group (P < 0.01).
Claims (3)
1. arklemin open capsule is characterized in that by following dosage being that the preparation of raw material of weight portion forms: Radix Salviae Miltiorrhizae 15-35, Radix Panacis Quinquefolii 10-30; Flos Carthami 10-30, Rhizoma Chuanxiong 8-21, Radix Notoginseng 3-9; Hirudo 2-8; Eupolyphaga Seu Steleophaga 2-8, Radix Aconiti Lateralis Preparata 1-3, arklemin open capsule method for preparing of the present invention is following: at first with the Radix Notoginseng for preparing, Hirudo, Eupolyphaga Seu Steleophaga, that Radix Aconiti Lateralis Preparata grinds into fine powder is subsequent use; Again with the Radix Salviae Miltiorrhizae for preparing, Rhizoma Chuanxiong, Radix Panacis Quinquefolii, Flos Carthami decocte with water twice, decocting water consumption for the first time is Radix Salviae Miltiorrhizae; Rhizoma Chuanxiong, Radix Panacis Quinquefolii, Flos Carthami gross weight 3-5 times, decocting time is 40 minutes, decocting water consumption for the second time is Radix Salviae Miltiorrhizae; Rhizoma Chuanxiong, Radix Panacis Quinquefolii, Flos Carthami gross weight 3-4 times; Decocting time 30 minutes decocts extracting solution with twice and merges filtration, filtrate for later use; Filtrating is put into concentration tank concentrate, be condensed into the fine powder that again Radix Notoginseng, Hirudo, Eupolyphaga Seu Steleophaga, Radix Aconiti Lateralis Preparata is ground behind the paste and add, carry out 100 degree oven drying at low temperatures then, pulverized 100 order fill capsules at last.
2. arklemin open capsule according to claim 1 is characterized in that said raw material consumption proportion is following: Radix Salviae Miltiorrhizae 20-30, Radix Panacis Quinquefolii 15-25, Flos Carthami 15-25, Rhizoma Chuanxiong 11-18, Radix Notoginseng 4-8, Hirudo 3-7, Eupolyphaga Seu Steleophaga 3-7, Radix Aconiti Lateralis Preparata 1.5-2.5.
3. arklemin open capsule according to claim 1 is characterized in that said raw material consumption proportion is following: Radix Salviae Miltiorrhizae 25, Radix Panacis Quinquefolii 21, Flos Carthami 21, Rhizoma Chuanxiong 15, Radix Notoginseng 6, Hirudo 5, Eupolyphaga Seu Steleophaga 5, Radix Aconiti Lateralis Preparata 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100878746A CN102600255A (en) | 2012-03-29 | 2012-03-29 | Coronary disease treatment capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100878746A CN102600255A (en) | 2012-03-29 | 2012-03-29 | Coronary disease treatment capsule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102600255A true CN102600255A (en) | 2012-07-25 |
Family
ID=46518274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100878746A Pending CN102600255A (en) | 2012-03-29 | 2012-03-29 | Coronary disease treatment capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102600255A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105168294A (en) * | 2015-08-14 | 2015-12-23 | 殷永洲 | Tablets for treatment for heart disease and preparation method thereof |
| CN107596280A (en) * | 2017-11-08 | 2018-01-19 | 马敏 | A kind of medicine for treating atherosclerosis and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1175458A (en) * | 1997-09-05 | 1998-03-11 | 张玉杰 | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases |
| CN101168042A (en) * | 2007-11-07 | 2008-04-30 | 周鲁菲 | Traditional Chinese medicine preparation for curing cardiovascular and cerebrovascular diseases and preparing method |
| CN101234137A (en) * | 2007-01-30 | 2008-08-06 | 米金铎 | Drug for curing coronary disease |
| CN101284046A (en) * | 2008-05-26 | 2008-10-15 | 北京市科威华食品工程技术有限公司 | Thrombus clear health soft capsules |
| US20100136146A1 (en) * | 2003-07-31 | 2010-06-03 | Xijun Yan | Composition for heart disease, its active ingredients, method to prepare same and uses thereof |
| CN102210835A (en) * | 2011-06-10 | 2011-10-12 | 卢超忠 | Traditional Chinese medicine for treating coronary disease |
-
2012
- 2012-03-29 CN CN2012100878746A patent/CN102600255A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1175458A (en) * | 1997-09-05 | 1998-03-11 | 张玉杰 | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases |
| US20100136146A1 (en) * | 2003-07-31 | 2010-06-03 | Xijun Yan | Composition for heart disease, its active ingredients, method to prepare same and uses thereof |
| CN101234137A (en) * | 2007-01-30 | 2008-08-06 | 米金铎 | Drug for curing coronary disease |
| CN101168042A (en) * | 2007-11-07 | 2008-04-30 | 周鲁菲 | Traditional Chinese medicine preparation for curing cardiovascular and cerebrovascular diseases and preparing method |
| CN101284046A (en) * | 2008-05-26 | 2008-10-15 | 北京市科威华食品工程技术有限公司 | Thrombus clear health soft capsules |
| CN102210835A (en) * | 2011-06-10 | 2011-10-12 | 卢超忠 | Traditional Chinese medicine for treating coronary disease |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105168294A (en) * | 2015-08-14 | 2015-12-23 | 殷永洲 | Tablets for treatment for heart disease and preparation method thereof |
| CN107596280A (en) * | 2017-11-08 | 2018-01-19 | 马敏 | A kind of medicine for treating atherosclerosis and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101020028B (en) | Chinese medicine for treating cardiac and cerebral vascular diseases | |
| CN100382839C (en) | Chinese-medicinal composition for treating coronary heart disease | |
| CN101822789B (en) | Hypotensor treating essential hypertension | |
| CN103055169A (en) | External use plaster for treating hypertensive disease | |
| CN101422562A (en) | Medicine for treating premature beat and atrial fibrillation | |
| CN104958490A (en) | Medicine for treating qi stagnation and blood stasis type coronary heart diseases and method for manufacturing medicine | |
| CN102600255A (en) | Coronary disease treatment capsule | |
| CN102512470B (en) | Pharmaceutical composition for treating cerebrovascular and cardiovascular diseases as well as preparation method and application | |
| CN1698804A (en) | Traditional Chinese medicine preparation for treating thoracic obstruction and palpitation and preparation method thereof | |
| CN102228618B (en) | Chinese medicinal powder for treating ischemic heart disease | |
| CN102198181B (en) | Antithrombotic and thrombosis-eliminating preparation | |
| CN101450106A (en) | Traditional Chinese medicine composition with ischemic myocardium angiogenesis promoting function | |
| CN107158347A (en) | A kind of pharmaceutical composition and preparation method and purposes for treating heart disease | |
| CN102579804B (en) | Chinese medicine for treating stenocardia | |
| CN102008539B (en) | Medicinal composition for treating diseases such as viral myocarditis and dilated cardiomyopathy and preparation process thereof | |
| CN102552715B (en) | Chinese medicinal composition, medicine containing Chinese medicinal composition and preparation method of medicine | |
| CN105770399A (en) | Traditional Chinese medicine composition for treating arrhythmia | |
| CN103239583B (en) | Airuike heart-soothing granule | |
| CN101698048A (en) | Traditional Chinese medicine ointment for treating high blood pressure and preparation method thereof | |
| CN101869689B (en) | External Chinese medicinal composition for treating angina pectoris coronary heart disease | |
| CN101716271B (en) | Chinese traditional medicine effective fraction composite used for curing coronary heart disease and preparation method thereof | |
| CN105168653A (en) | Traditional Chinese medicine composition used for treating coronary heart disease | |
| CN1682972A (en) | Chinese medicine composition for treating cardiovascular disease and its preparing method | |
| CN102614411B (en) | Chinese medicinal preparation for treating coronary heart disease angina pectoris and preparation method thereof | |
| CN105012655A (en) | Traditional Chinese medicinal composition for treating dilated cardiomyopathy and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120725 |
|
| WD01 | Invention patent application deemed withdrawn after publication |